MedTrace Logo

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

NCT05980416 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2025-11-14

Study results available
· View outcomes & findings →

Summary

This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.

Conditions

  • Stomach Neoplasm
  • Gastrointestinal Neoplasms
  • Digestive System Neoplasm
  • Neoplasms by Site
  • Neoplasms

Interventions

DRUG

EO-3021

Anti-Claudin 18.2 antibody drug conjugate

DRUG

Ramucirumab (CYRAMZA®)

VEGFR2 inhibitor

DRUG

Dostarlimab

anti-PD-1 antibody

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2025-05-07
Completion
2025-06-02
FDA Drug
Yes

Countries

  • United States
  • Japan
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05980416 on ClinicalTrials.gov